These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27084892)

  • 41. Advances in understanding drug metabolism and its contribution to variability in patient response.
    Tucker GT
    Ther Drug Monit; 2000 Feb; 22(1):110-3. PubMed ID: 10688271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytochrome P450s and other enzymes in drug metabolism and toxicity.
    Guengerich FP
    AAPS J; 2006 Mar; 8(1):E101-11. PubMed ID: 16584116
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biotransformation of drugs in human skin.
    Svensson CK
    Drug Metab Dispos; 2009 Feb; 37(2):247-53. PubMed ID: 19005027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown.
    Alfaro CL
    Psychopharmacol Bull; 2001; 35(4):80-93. PubMed ID: 12397858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biotransformation of the anthraquinones emodin and chrysophanol by cytochrome P450 enzymes. Bioactivation to genotoxic metabolites.
    Mueller SO; Stopper H; Dekant W
    Drug Metab Dispos; 1998 Jun; 26(6):540-6. PubMed ID: 9616189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism.
    Guengerich FP
    Pharmacol Rev; 2024 Oct; 76(6):1104-1132. PubMed ID: 39054072
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
    Avent KM; DeVoss JJ; Gillam EM
    Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Compound lipophilicity for substrate binding to human P450s in drug metabolism.
    Lewis DF; Jacobs MN; Dickins M
    Drug Discov Today; 2004 Jun; 9(12):530-7. PubMed ID: 15183161
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peroxidases: a role in the metabolism and side effects of drugs.
    Tafazoli S; O'Brien PJ
    Drug Discov Today; 2005 May; 10(9):617-25. PubMed ID: 15894226
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of cytochrome P450 mediated metabolism.
    Olsen L; Oostenbrink C; Jørgensen FS
    Adv Drug Deliv Rev; 2015 Jun; 86():61-71. PubMed ID: 25958010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chimeric cytochromes P450 engineered by domain swapping and random mutagenesis for producing human metabolites of drugs.
    Kang JY; Ryu SH; Park SH; Cha GS; Kim DH; Kim KH; Hong AW; Ahn T; Pan JG; Joung YH; Kang HS; Yun CH
    Biotechnol Bioeng; 2014 Jul; 111(7):1313-22. PubMed ID: 24474032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450.
    Yu L; Waxman DJ
    Drug Metab Dispos; 1996 Nov; 24(11):1254-62. PubMed ID: 8937861
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiple activated oxygen species in P450 catalysis: contributions To specificity in drug metabolism.
    Coon MJ; Vaz AD; McGinnity DF; Peng HM
    Drug Metab Dispos; 1998 Dec; 26(12):1190-3. PubMed ID: 9860926
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm.
    Gelboin HV; Krausz K
    J Clin Pharmacol; 2006 Mar; 46(3):353-72. PubMed ID: 16490812
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar.
    Zhang D; Wang L; Chandrasena G; Ma L; Zhu M; Zhang H; Davis CD; Humphreys WG
    Drug Metab Dispos; 2007 Jan; 35(1):139-49. PubMed ID: 17062778
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
    Isvoran A; Louet M; Vladoiu DL; Craciun D; Loriot MA; Villoutreix BO; Miteva MA
    Drug Discov Today; 2017 Feb; 22(2):366-376. PubMed ID: 27693711
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development.
    Fukami T; Yokoi T; Nakajima M
    Annu Rev Pharmacol Toxicol; 2022 Jan; 62():405-425. PubMed ID: 34499522
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human P450s in the metabolism of drugs: molecular modelling of enzyme-substrate interactions.
    Lewis DF
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):5-8. PubMed ID: 16922648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytochromes P450: decision-making tools for personalized therapeutics.
    Murray M; Petrovic N
    Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.